Clarity Signs Copper 64 Supply Agreement with The University of Queensland.

Clarity Pharmaceuticals (ASX: CU6) has signed a new agreement with The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) for the supply of copper-64 (Cu-64). This supply will support Clarity’s manufacturing of 64Cu-SAR-bisPSMA for Phase III CLARIFY and AMPLIFY registrational trials, the Co-PSMA investigator-initiated trial, and the SECuRE theranostic trial in Australia. Additionally, it will aid pre-clinical programs, including SAR-bisFAP and SAR-trastuzumab. 

The agreement strengthens Clarity’s collaboration with UQ and ensures a stable supply of Cu-64 through AIBN’s cyclotron and radiochemistry facilities. Cu-64’s longer half-life enables next-day imaging, improving prostate cancer detection and logistics over traditional isotopes. Clarity’s 64Cu-SAR-bisPSMA has shown superior tumor retention and lesion detection benefits. With recent FDA Fast Track Designations, the agreement supports Clarity’s goal of advancing prostate cancer diagnostics and expanding access to next-generation radiopharmaceuticals.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com